Healthcare, Pharma & Life Sciences

Forum Health Names Elizabeth Campbell CFO and Development Officer

Image
Forum Health Names Elizabeth Campbell CFO and Development Officer

Lisle, Ill. – – September 30, 2026 -- Forum Health, LLC has appointed Elizabeth Campbell as Chief Financial and Development Officer, a newly created role tasked with leading fundraising and acquisitions as the functional medicine network pursues rapid expansion.

Campbell joins after building and selling a 88-clinic orthodontic platform

Campbell co-founded myOrthos, LLC in 2019 and served as CEO, completing 37 acquisitions to build a platform of 88 clinics across 14 states before its 2025 sale to Smile Doctors, a portfolio company of TH Lee. She brings more than 20 years of experience spanning The Boston Consulting Group, private equity roles at SV Life Sciences Advisors and LLR Partners, and healthcare operating leadership.

Zifo: Fragmented CMC Data Creates 'Billion-Dollar Bottleneck' in Biopharma

Image
Zifo: Fragmented CMC Data Creates 'Billion-Dollar Bottleneck' in Biopharma

Cambridge, Mass. – September 30, 2026 -- Biopharma companies are losing time and money to a recurring pattern of disconnected experiments and manual data reconciliation that Zifo calls the 'DMTA doom loop,' according to a new position paper from the scientific informatics firm.

Zifo identifies a structural flaw in the Design-Make-Test-Analyse process

The paper, titled 'The Billion-Dollar Bottleneck: Why CMC Is Strangling the Biopharma Pipeline,' argues that the DMTA cycle used in chemistry, manufacturing and controls (CMC) work is forced into a rigid, linear execution model rather than adapting to what the science actually requires. Zifo says evidence in many CMC environments is scattered across scientific applications, instruments, spreadsheets, PDFs, batch records and individual expertise, forcing scientists to reconstruct experimental histories and decision reasoning before they can even begin new work.

Suvoda Unifies Clinical Trial Platform, Cuts RTSM Setup Time 80%

Image
Suvoda Unifies Clinical Trial Platform, Cuts RTSM Setup Time 80%

Conshohocken, Pa. – – September 30, 2026 -- Suvoda has released a unified clinical trial technology platform that merges its RTSM systems with Greenphire's financial management tools, cutting kickoff-to-UAT timelines by up to 80% through new agentic AI capabilities.

Agentic AI Slashes Setup Times Across RTSM and eCOA

Suvoda's new AI layer, starting with randomization and trial supply management (RTSM) and electronic clinical outcome assessment (eCOA), is delivering the 80% reduction in kickoff-to-UAT timelines. A conversational assistant called Sofia allows sponsors and sites to query data and execute permissioned actions across multiple languages, with every action logged for audit purposes while humans retain final sign-off authority.

Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Image
Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).

Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Image
Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

SUANNUTRA Localizes Lemon Verbena Supply Chain in Valencia, Spain

Image
SUANNUTRA Localizes Lemon Verbena Supply Chain in Valencia, Spain

Madrid – September 30, 2026 -- SUANNUTRA SA has relocated cultivation of lemon verbena, a key botanical input for its branded ingredients, from South America to farms in Valencia, Spain, aiming to secure a more resilient and traceable supply chain.

SUANNUTRA shifts lemon verbena sourcing from the Andes to Valencia farms

The plant, native to South America and traditionally used by Andean healers as a digestive aid and antispasmodic remedy, now anchors three of SUANNUTRA's branded ingredients: Metabolaid®, RelaxPLX®, and Elissara®. "Growing it locally with full control from planting to final product reinforces our commitment to responsible botanical sourcing," said Jaime Durán Sanz, Chief Business Officer for SUANNUTRA.

Servier Standardizes Data Across 80+ Countries With Veeva OpenData

Image
Servier Standardizes Data Across 80+ Countries With Veeva OpenData

Barcelona – September 30, 2026 -- Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, part of a global push to build an AI-ready data foundation for its commercial and medical teams.

Servier scales AI infrastructure after prior success with Veeva Link Key People

The French pharmaceutical company, governed by a Foundation, is harmonizing customer reference data globally to create a unified semantic layer that connects with Veeva Link. Liam Hanrahan, director of world operations excellence at Servier, said the move goes beyond process improvement, calling it the construction of a global data foundation designed to redefine how the company operates and scale AI across its affiliates.

Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Image
Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

Image
Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.

Astrocyte Raises $9.5M Series B as Concussion Drug Trial Completes Enrollment

Image
Astrocyte Raises $9.5M Series B as Concussion Drug Trial Completes Enrollment

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

DeepWork Capital leads financing with four new investors joining the round

The Series B was led by DeepWork Capital, with continued backing from existing investors and new participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures. Jackson Streeter, M.D., Venture Partner at DeepWork Capital, said the firm has been impressed by the consistency of Astrocyte's science and the progress of its clinical programs.